<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        119-9-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRILEPTAL 150MG F.C TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OXCARBAZEPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AF02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Trileptal is</strong></p><p>Trileptal contains the active substance oxcarbazepine.</p><p>Trileptal belongs to a group of medicines called anticonvulsants or antiepileptics.</p><p>&nbsp;</p><p><strong>What Trileptal is used for</strong></p><p>Medicines such as Trileptal are the standard treatment for epilepsy.</p><p>Epilepsy is a brain disorder that causes people to have recurring seizures and convulsions. Seizures happen because of a temporary fault in the brain&rsquo;s electrical activity. Normally brain cells coordinate body movements by sending out signals through the nerves to the muscles in an organised, orderly way. In epilepsy, brain cells send out too many signals in a disorderly fashion. The result can be uncoordinated muscular activity that is called an epileptic seizure.</p><p>&nbsp;</p><p>Trileptal is used to treat partial seizures with or without secondarily generalised tonic-clonic seizures.&nbsp; Partial seizures involve a limited area of the brain, but may spread to the whole brain and may cause a generalised tonic-clonic seizure. There are two types of partial seizures: simple and complex. In simple partial seizures, the patient remains conscious, whereas in complex partial seizures, patients consciousness is altered.</p><p>&nbsp;</p><p>Trileptal works by keeping the brain&rsquo;s &ldquo;overexcitable&rdquo; nerve cells under control.&nbsp; This suppresses or reduces the frequency of such seizures.</p><p>&nbsp;</p><p>Trileptal can be used alone or in combination with other antiepileptic medicines.</p><p>&nbsp;</p><p>Usually, the doctor will try to find the one medicine that works best for you or for your child.&nbsp; However, with more severe epilepsy, a combination of two or more medicines may be needed to control seizures.</p><p>&nbsp;</p><p>Trileptal is for use in adults and in children of 6 years of age and above.</p><p>&nbsp;</p><p>If you have any questions about how Trileptal works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Before you take Trileptal</strong></p><p>&nbsp;</p><p>Follow all your doctor&rsquo;s instructions carefully, even if they differ from the general information contained in this leaflet.</p><p>&nbsp;</p><p><strong>Monitoring during your treatment with Trileptal</strong></p><p>Before and during your treatment with Trileptal, your doctor may perform blood tests to determine the dose for you. Your doctor will tell you when to have the tests.</p><p><strong>&nbsp;</strong></p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take Trileptal</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic</strong> to oxcarbazepine or any of the other ingredients of this medicine (listed in section 6) or if you are allergic to eslicarbazepine.</p><p>If this applies to you, tell your doctor before taking Trileptal. If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with Trileptal</strong></p><p>Talk to your doctor or<strong> </strong>pharmacist before taking Trileptal:<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever shown <strong>unusual sensitivity</strong> (rash or any other signs of allergy) to carbamazepine or to any other medicines. If you are allergic to carbamazepine, the chances are approximately 1 in 4 (25 %) that you could also have an allergic reaction to oxcarbazepine (Trileptal).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>kidney disease</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have serious <strong>liver disease</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>taking diuretics</strong> (medicines used to help the kidneys get rid of salt and water by increasing the amount of urine produced).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>heart disease</strong>, shortness of breath and/or swelling of the feet or legs due to fluid</p><p>build-up.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your <strong>blood level of sodium is low</strong> as shown by blood tests (see section 4 Possible side effects).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a woman <strong>taking a hormonal contraceptive</strong> (such as &ldquo;the birth-control pill&rdquo;), Trileptal may stop your contraceptive from working. &nbsp;Use a different or extra (non-hormonal) method of contraception while taking Trileptal. This should help to prevent an unwanted pregnancy. Tell your doctor immediately if you get irregular vaginal bleeding or spotting. If you have any questions about this, ask your doctor or health professional.</p><p>&nbsp;</p><p>The risk of serious skin reactions in patients of Han Chinese or Thai origin associated with carbamazepine or chemically-related compounds may be predicted by testing a blood sample of these patients. Your doctor should be able to advise if a blood test is necessary before taking oxcarbazepine.</p><p>&nbsp;</p><p><strong>If you develop any of the following symptoms after starting Trileptal, tell your doctor immediately or go to the emergency department at your nearest hospital:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience an <strong>allergic reaction</strong> after starting Trileptal. Symptoms include swelling of lips, eyelids, face, throat, mouth, or sudden breathing problems, fever with swollen glands, rash or skin blistering.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you notice symptoms of <strong>hepatitis</strong>, such as jaundice (yellowing of skin or the whites of the eyes).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience an increase in the frequency of seizures. This is particularly important for children but may also occur in adults.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you notice possible symptoms of <strong>blood disorders</strong> such as tiredness, being short of breath when exercising, looking pale, headache, chills, dizziness, frequent infections leading to fever, sore throat, mouth ulcers, bleeding or bruising more easily than normal, nose bleeds, reddish or purplish patches, or unexplained blotches on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a small number of people being treated with antiepileptics such as Trileptal have had thoughts of harming or killing themselves.&nbsp; If at any time you have these thoughts, immediately contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; if you have a <strong>fast or unusually slow heart beat.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermalnecrolysis) have been reported very rarely &nbsp;with the use of oxcarbazepine, appearing initially as reddishtarget-like spots orcircular patches often with central blisters on the trunk</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional signs to look for include ulcers in the mouth, throat, and nose, genitals andconjunctivitis (red and swollen eyes) .These potentially life-threatening skin rashes are often accompanied byflu-like symptoms.The rash may progress to widespread blistering or peeling of the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The highest risk for occurrence of serious skin reactions is within the first 3 weeks of treatment in general.&nbsp; There is an increased risk of these reactions occurring in patients of Han Chinese, Thai or other Asian origin (see below, &ldquo;Patients of Han Chinese or Thai origin&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of oxcarbazepine, you must not be re-started on oxcarbazepine at any time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell them that you are taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine can lead to a condition called hypothyroidism (low levels of thyroid hormone). If you are a child, your doctor may examine your blood at regular intervals after starting treatment with Oxcarbazepine &ldquo;</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>In children, your doctor may recommend thyroid function monitoring before therapy and during therapy.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.&nbsp;</p><p>This applies especially to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormonal contraceptives, such as the pill<strong> </strong>(see Take special care with Trileptal).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other antiepileptic and enzyme inducing medicines, such as carbamazepine, phenobarbital, phenytoin or lamotrigine and rifampicin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that reduce the level of sodium in your blood, such as diuretics (used to help the kidneys get rid of salt and water by increasing the amount of urine produced), desmopressin and non-steroidal anti-inflammatory medicines, such as indometacin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium and monoamine oxidase inhibitors (medicines used to treat mood swings and some types of depression).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that control the body&rsquo;s immune system, such as ciclosporin and tacrolimus.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking Trileptal with food and drink</strong></p><p>Trileptal can be taken with or without food.</p><p>&nbsp;</p><p>Alcohol may increase the sedative effects of Trileptal. Avoid alcohol as much as possible and ask your doctor for advice.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy and breast-feeding </strong></p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is important to control epileptic seizures during pregnancy. However, there may be a risk to your baby if you take antiepileptic medicines during pregnancy.</p><p>&nbsp;</p><p>Birth defects</p><p>Studies have not shown an increased risk of birth defects associated with oxcarbazepine use during pregnancy, however, a risk of birth defects for your unborn child cannot be completely ruled out.&nbsp;</p><p>Neurodevelopmental disorders</p><p>Some studies have shown that exposure to oxcarbazepine in the womb negatively affects the development of brain function (neurodevelopment) in children, while other studies have not found such an effect. The possibility of an effect on neurodevelopment cannot be ruled out.4</p><p>&nbsp;</p><p>Your doctor will tell you the benefits and potential risks involved and help you to decide whether you should take Trileptal.</p><p>&nbsp;</p><p>Do not stop your treatment with Trileptal during pregnancy without first checking with your doctor.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>&nbsp;If you are taking this medicine, ask your doctor for advice before starting breastfeeding. The active substance in Trileptal passes into breast milk. Although available data suggest that the amount of Trileptal that passes to a breastfed baby is low, a risk of side effects for the baby cannot be ruled out.&nbsp; Your doctor will discuss with you the benefits and potential risks of breastfeeding while taking Trileptal. If you are breastfeeding while taking Trileptal and you think your baby is having side effects such as excessive sleepiness or poor weight gain, tell your doctor immediately.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>Trileptal may make you feel sleepy or dizzy, or may cause blurred vision, double vision, lack of muscle coordination or a depressed level of consciousness, especially when starting treatment or increasing the dose.</p><p>It is important to discuss with your doctor whether you can drive a vehicle or operate machines while taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Trileptal exactly as your doctor or pharmacist has told you, even if this differs from the information given in this leaflet. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>How much to take</strong></p><p><strong>Dose for adults</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The<strong> usual starting dose </strong>of Trileptal for adults (including elderly patients) is 600 mg per day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take one 300 mg tablet twice daily or two 150 mg tablets twice daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may increase the dose gradually to find the best dose for you. The best results are usually with doses between 600 and 2,400 mg per day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take another antiepileptic medicine, the dose is the same.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney disease (with impaired kidney function), the starting dose is half the usual starting dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver disease, your doctor may adjust your dose.</p><p>&nbsp;</p><p><strong>Dose for children</strong></p><p>Trileptal can be taken by children aged 6 years or above.</p><p>&nbsp;</p><p>The dosage for children depends on their weight.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is 8 to 10 milligrams per kilogram of bodyweight per day given in two divided doses. For example, a 30-kg child would start treatment with one 150 mg tablet twice daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may increase the dose gradually to find the best dose for your child. The best results are usually with a dose of 30 milligrams per kilogram of bodyweight per day. The maximum dose for a child is 46 milligrams per kilogram of bodyweight per day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trilepta is not recommended for children under 6 years old since it has not been shown to be a safe and effective treatment in this age group&rdquo;</p><p>&nbsp;</p><p><strong>How to take Trileptal</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets with a little water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If necessary, the tablets can be broken in half to help swallow them.&nbsp; Do not break the tablets to take only half of the dose. The score line was not designed for dividing the tablet into equal doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For small children who cannot swallow tablets, or who cannot be given the necessary dose in tablet form, Trileptal is available as an oral suspension.</p><p>&nbsp;</p><p><strong>When and for how long to take Trileptal</strong></p><p>Take Trileptal twice a day, every day, at about the same time of day, unless the doctor tells you otherwise.&nbsp; This will have the best effect on controlling epilepsy.&nbsp; It will also help you to remember when to take the tablet(s).</p><p>&nbsp;</p><p>Your doctor will tell you how long your or your child&rsquo;s treatment with Trileptal will last. The length of treatment will depend on your or your child&rsquo;s seizure type.&nbsp; Treatment may be needed for many years to control the seizures. Do not change the dose or stop treatment without talking to your doctor.</p><p>&nbsp;</p><p><strong>a.If you take more Trileptal than you should</strong></p><p>If you have taken more tablets than your doctor prescribed, contact the nearest hospital or your doctor immediately. Symptoms of overdose with Trileptal may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, dizziness, problems with coordination and/or involuntary movement of the eyes, muscular twitching or significant worsening of convulsions, headache, loss of consciousness, coma,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), being sick (vomiting), increased uncontrolled movements,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lethargy, double vision, narrowing of black part of the eye, blurred vision,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; short and shallow breathing (respiratory rate depression),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat (QTc prolonged interval),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling, headache, coma, decreased consciousness, uncontrollable movements of mouth, tongue and limbs,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression, agitation, confusion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness.</p><p>&nbsp;</p><p><strong>b.If you forget to take Trileptal</strong></p><p>If you have forgotten one dose, take it as soon as you remember. However, if it is time for your next dose, do not take the missed dose. Go back to your regular dosing timetable. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you are unsure or have forgotten to take several doses, contact your doctor.</p><p>&nbsp;</p><p>c.If you stop taking Trileptal</p><p>Do not stop taking your medicine unless your doctor tells you to.</p><p>&nbsp;</p><p>To prevent sudden worsening of your seizures, never discontinue your medicine abruptly.</p><p>&nbsp;</p><p>If your treatment is stopped, it should be done gradually as instructed by your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong><em>Tell your doctor immediately or go to the emergency department at your nearest hospital if you get any of the following side effects:</em></strong></p><p>The following are signs of very rare (may affect up to 1 in 10,000 people), but potentially serious side effects that may require urgent medical treatment. The doctor will also decide whether Trileptal has to be stopped immediately and how to continue further medical care.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the lips, eyelids, face, throat or mouth, accompanied by difficulty in breathing, speaking or swallowing (signs of anaphylactic reactions and angioedema) or other signs of hypersensitivity reactions such as skin rash, fever, and pain in the muscles and joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe blistering of the skin and/or mucous membranes of the lips, eyes, mouth, nasal passages or genitals (signs of serious allergic reaction including Lyell&rsquo;s syndrome, Stevens-Johnson syndrome and erythema multiforme).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, shortness of breath when exercising, looking pale, headache, chills, dizziness, frequent infections leading to fever, sore throat, mouth ulcers, bleeding or bruising more easily than normal, nose bleeds, reddish or purplish patches, or unexplained blotches on the skin (signs of a decrease in the number of blood platelets or decrease in the number of blood cells).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red blotchy rash mainly on face which may be accompanied by fatigue, fever, feeling sick (nausea) or loss of appetite (signs of systemic lupus erythematosus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lethargy, confusion, muscle twitching or significant worsening of convulsions (possible symptoms of low sodium levels in the blood) (see Take special care with Trileptal).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms with jaundice (yellowing of the skin or the whites of the eyes) (signs of hepatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe upper stomach (abdominal) pain, being sick (vomiting), loss of appetite (signs of inflammation of the pancreas).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain, tiredness, hair loss, muscle weakness, feeling cold (signs of under active thyroid gland).</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor as soon as possible if you get any of the following side effects, </strong>they may require medical attention:</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling; coordination problems; involuntary movement of the eyes; anxiety and nervousness; depression, mood swing; rash.</p><p><strong>Very rare</strong><strong> </strong>(may affect up to 1 in 10,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat or a very fast or slow heart rate.</p><p>&nbsp;</p><p><strong>Other side effects <em>that may occur</em>: </strong></p><p>These are usually mild to moderate side effects of Trileptal. &nbsp;Most of these effects are transient and usually diminish over time.</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness; headache; dizziness; drowsiness; feeling sick (nausea); being sick (vomiting); double vision.</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness; memory disturbances; impaired concentration; apathy; agitation; confusion; blurred vision; visual disturbance; constipation; diarrhoea; stomach (abdominal) pain; acne; hair loss, balance disturbances; weight increased.</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives. You may also have raised levels of liver enzymes while taking Trileptal.</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure, speech disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; there have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures.&nbsp; Check with your doctor or pharmacist if you are on long-term antiepileptic medication, have a history of osteoporosis or take steroids.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased thyroxine in the blood, seen in a thyroid function test</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fall</p><p>Red, swollen skin with small pus-filled spots (Acute Generalised Exanthematous Pustulosis (AGEP)) &ldquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&ordm;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the blister and the outer carton.&nbsp; The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance of Trileptal is oxcarbazepine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trileptal 150 mg film-coated tablets</p><p>Each film-coated tablet contains 150 mg of oxcarbazepine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trileptal 300 mg film-coated tablets</p><p>Each film-coated tablet contains 300 mg of oxcarbazepine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trileptal 600 mg film-coated tablets</p><p>Each film-coated tablet contains 600 mg of oxcarbazepine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><strong>Tablet core</strong>: silica colloidal anhydrous, microcrystalline cellulose, hypromellose, crospovidone, magnesium stearate.</p><p><strong>&nbsp;</strong></p><p><strong>Tablet coating</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>150 mg</strong> tablet: hypromellose, macrogol 4000, yellow iron oxide (E 172), red iron oxide (E 172), black iron oxide (E 172), talc, titanium dioxide (E 171);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>300 mg</strong> tablet: hypromellose, macrogol 8000, yellow iron oxide (E 172), talc, titanium dioxide (E 171);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>600 mg</strong> tablet: hypromellose, macrogol 4000, red iron oxide (E 172), black iron oxide (E 172), talc, titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Trileptal 150 mg film-coated tablets are pale grey green, ovaloid, scored on both sides and embossed with T/D on one side and C/G on the other side.

Trileptal 300 mg film-coated tablets are yellow, ovaloid, scored on both sides, and embossed with TE/TE on one side and CG/CG on the other side.

Trileptal 600 mg film-coated tablets are light pink, ovaloid, scored on both sides, and embossed with TF/TF on one side and CG/CG on the other side.

Trileptal film-coated tablets are available in blister packs of 30, 50, 100, 200 and 500 tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d.	This leaflet was last approved in May 2018 by MHRA.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو تريليبتال.</strong></p><p dir="RTL">يحتوي عقار تريليبتال على المادة الفعّالة أوكسكاربازيبين.</p><p dir="RTL">ينتمي عقار تريليبتال إلى مجموعة من الأدوية تُسمى مضادات التشنج أو مضادات الصرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وما هي دواعي استعماله.</strong></p><p dir="RTL">تُعَد الأدوية التي على شاكلة عقار تريليبتال علاجات قياسية لعلاج الصَّرَع.</p><p dir="RTL">الصَّرَع هو اضطراب بالمخ يُسبب حدوث نوبات صرع وتشنجات متكررة للأشخاص. تحدث النوبات التشنُّجية بسبب خطأ مؤقت في النشاط الكهربائي للمخ. عادةً تقوم خلايا المخ بتنسيق حركات الجسم عن طريق إرسال إشارات من خلال الأعصاب إلى العضلات بطريقة منظمة ومتناسقة. في حالات الصَّرع، ترسل خلايا المخ إشارات كثيرة جدًّا بطريقة غير منظمة. قد تكون النتيجة حدوث نشاط عضلي غير متناسق وهو ما يُسمى بنوبة الصرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدَم عقار تريليبتال لعلاج النوبات التشنجية الجزئية مع أو بدون النوبات التشنجية التوترية- الرمعية المُتعممة الثانوية. تشمل النوبات التشنُّجية الجزئية منطقة محدودة من المخ، ولكن قد تنتشر في المخ بالكامل وقد تسبب حدوث نوبة تشنّجية توترية- رمعية مُتعَممة. هناك نوعان من النوبات التشنُّجية الجزئية: البسيطة والمركبة (المعقدة). في النوبات التشنُّجية الجزئية البسيطة، يظل المريض واعيًا، في حين أنه في النوبات التشنُّجية الجزئية المركبة (المعقدة) يتغير وعي المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل عقار تريليبتال عن طريق الحفاظ على الخلايا العصبية &quot;مفرطة الإثارة&quot; بالمخ تحت السيطرة. وهذا يثبط أو يقلل معدّل تكرار هذه النوبات التشنُّجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُستخدم عقار تريليبتال بمفرده أو بمصاحبة أدوية أخرى مضادة للصرع.&nbsp;</p><p dir="RTL">عادةً سيحاول الطبيب العثور على دواء واحد يعمل بأفضل صورة مُمكِنة لك أو لطفلك. ومع ذلك، مع حالات الصَّرع الأكثر شدة، قد يستلزم الأمر الجمع بين دواءين أو أكثر للسيطرة على النوبات التشنُّجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار تريليبتال مُخَصص للاستخدام في البالغين وفي الأطفال من سن 6 سنوات فأكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة حول كيفية عمل عقار تريليبتال أو لماذا تم وصف هذا الدَّواء لك، فاستشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">اتبع جميع تعليمات طبيبك بعناية، حتى إذا كانت تختلف عن المعلومات العامة الواردة في هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراقبة أثناء علاجك بعقار </strong><strong>تريليبتال</strong></p><p dir="RTL">قد يجري طبيبك اختبارات دم قبل وأثناء علاجك بعقار تريليبتال؛ لتحديد الجرعة المناسبة لك. وسيخبرك طبيبك بالوقت الذي يجب عليك فيه إجراء الاختبارات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ&zwnj;.موانع استعمال تريليبتال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أوكسكاربازيبين أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6) أو إذا كنت تعاني من حساسية تجاه إيسليكاربازيبين.</p><p dir="RTL">إذا كان هذا ينطبق عليك، أخبر طبيبك قبل تناول عقار تريليبتال. إذا كنت تعتقد أنك قد تكون لديك حساسية، فاستشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب.الاحتياطات عند استعمال تريليبتال </strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار تريليبتال:<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت لديك <strong>حساسية غير مُعتادة</strong> (طفح جلدي أو أي علامات حساسية أخرى) من قبل تجاه كَرْبامازِيبين أو تجاه أيَّة أدوية أخرى. إذا كانت لديك حساسية تجاه كَرْبامازِيبين، فهناك احتمالات بما يقرب من 1 من كل 4 (25٪) لإصابتك أيضًا بتفاعل حساسية تجاه أوكسكاربازيبين (عقار تريليبتال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا <strong>بمرض كلوي</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>مرض كبدي</strong> خطير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>كنت تتناول مُدِرات البول</strong> (أدوية تُستَخدَم لمساعدة الكُلى على التَّخلص من الملح والماء عن طريق زيادة كمية البول التي يتم إخراجها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا <strong>بمرض قلبي</strong>، ضيق بالتَّنفس و/ أو تورُّم في القدمين أو الساقين بسبب تراكم السَّوائل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت اختبارات الدَّم تظهر أن <strong>مستويات الصوديوم بالدَّم لديك منخفضة</strong> (انظر قسم 4: الاعراض الجانبية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ سيدة<strong> تتناول أحد موانع الحَمْل الهرمونية</strong> (مثل: &quot;حبوب منع الحَمْل&quot;)، فقد يُؤدي عقار تريليبتال إلى إيقاف مفعول مانع الحَمْل.&nbsp; استخدمي وسيلة مختلفة أو إضافية (غير هرمونية) لمنع الحَمْل أثناء تناوُل عقار تريليبتال. سيُساعِد هذا في منع حدوث حَمْل غير مرغوب فيه. أخبري طبيبكِ فورًا إذا أُصِبت بنزيف مهبلي غير منتظم أو تساقط قطرات دم. إذا كانت لديكِ أية أسئلة حول ذلك، اسألي طبيبك أو أخصائي الصحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكِن توقع خطورة حدوث تفاعلات جلدية خطيرة في المرضى من أصول هان صينية أو تايلاندية مُصاحبة لكَرْبامازِيبين أو المركبات ذات الصلة من النَّاحية الكيميائية عن طريق اختبار عينة دم من هؤلاء المرضى. سيكون بإمكان طبيبك نصحك بما إذا كان إجراء اختبار الدَّم ضروريًّا قبل تناوُل أوكسكاربازيبين أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أُصبت بأي من الأعراض التَّالية بعد بدء العلاج بعقار </strong><strong>تريليبتال</strong><strong>، أخبر طبيبك على الفور أو اذهب لقسم الطوارئ بأقرب مستشفى إليك:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرَّضت <strong>لتفاعل حساسية</strong> بعد بدء العلاج بعقار تريليبتال. الأعراض تشمل: تورُّم الشفتين أو الجفون أو الوجه أو الحَلْق أو الفم أو مشاكل التَّنفس المفاجئة أو &nbsp;حُمّى يُصاحِبها تورُّم الغدد أو طفحًا جلديًّا أو ظهور بثور على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت حدوث أعراض <strong>التهاب الكبد</strong>، مثل: اليرقان (اصفرار الجلد أو اصفرار بياض العينين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرَّضت لزيادة في مُعدَّل تكرار حدوث النوبات التشنُّجية. يكون هذا عرَضًا مُهِمًّا بشكل خاص للأطفال ولكن قد يحدث أيضًا في البالغين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت حدوث أعراض مُحتَمَلة <strong>لاضطرابات الدَّم </strong>مثل: التَّعب، الشعور بضيق التَّنفس عند ممارسة التمارين الرياضية، الشحوب، الصداع، القشعريرة، الدوخة، العدوى المتكررة التي تُؤدي إلى حدوث حُمّى، التهاب الحَلْق، قُرَح الفم، حدوث نزيف أو كدمات بصورة أسهل من المُعتاد، نزيف من الأنف، ظهور بقع حمراء أو أرجوانية أو ظهور بقع على الجلد ليس لها مبرر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد عانى عدد قليل من الأشخاص الذين يتم علاجهم بمضادات الصرع مثل عقار تريليبتال من أفكار لإيذاء أنفسهم أو الانتحار.&nbsp; يجب أن تتصل بطبيبك فورًا إذا ساورتك هذه الأفكار في أي وقت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من <strong>تسارع ضربات القلب أو بطئها بشكل غير مُعتاد.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات إضافية للبحث عنها تشمل القرح في الفم والحلق والأنف والأعضاء التناسلية والتهاب الملتحمة (العينان الحمراء والمنتفخة). وغالبًا ما تكون الطفح الجلدي الذي يهدد الحياة مصحوبًا بأعراض شبيهة بالأنفلونزا. قد يتطور الطفح الجلدي إلى ظهور تقرحات أو تقشر الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلى خطر لحدوث ردود فعل جلدية خطيرة هو خلال الأسابيع الثلاثة الأولى من العلاج بشكل عام. هناك خطر متزايد من حدوث ردود الفعل هذه في مرضى الهان الصينيين أو التايلانديين أو من أصل آسيوي آخر (انظر أدناه ، &quot;المرضى من أصل هان الصيني أو التايلاندي&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بمتلازمة ستيفنز جونسون أو تنخرت البشرة عن طريق الجلد مع استخدام اوكسكاربازيبين ، فيجب ألا تبدأ اوكسكاربازيبين من جديد في أي وقت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت عليك طفح جلدي أو هذه الأعراض الجلدية ، فاطلب المشورة الفورية من الطبيب وأخبرهم أنك تتناول هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا الدواء يمكن أن يؤدي إلى حالة تسمى قصور الغدة الدرقية (انخفاض مستويات هرمون الغدة الدرقية). إذا كنت طفلاً ، قد يفحص طبيبك دمك على فترات منتظمة بعد بدء العلاج مع اوكسكاربازيبين</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">في الأطفال، قد يوصيك طبيبك بإجراء مراقبة لوظائف الغدة الدَّرقية قبل العلاج وخلاله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.&nbsp;</p><p dir="RTL">ينطبق هذا بشكل خاص على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحَمْل الهرمونية، مثل: حبوب منع الحَمْل (انظر: تحذيرات واحتياطات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الصَّرَع الأخرى والأدوية المُحفزة للإنزيمات، مثل: كَرْبامازِيبين أو فينوباربيتال أو فينيتوين أو لاموتريجين وريفامبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تخفض مستوى الصوديوم لديك بالدَّم، مثل: مُدِرات البول (التي تُستَخدَم لمساعدة الكُلى على التَّخلص من الملح والماء عن طريق زيادة كمية البول التي يتم إخراجها)، ديزموبريسين ومضادات الالتهاب غير الستيرويدية، مثل: إندوميتاسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم ومثبطات الأوكسيديز أحادي الأمين (أدوية تُستَخدَم لعلاج تقلبات الحالة المزاجية وبعض أنواع الاكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تتحكم في الجهاز المناعي للجسم، مثل: سيكلوسبورين وتاكروليموس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. تناول تريليبتال مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناوُل عقار تريليبتال مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد تناول الكحوليات من التَّأثيرات المُهَدئة لعقار تريليبتال. تجنَّب تناوُل الكحوليات قدر الإمكان واستشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. الحمل والرضاعة</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنتِ حاملًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تناوُل هذا الدَّواء.</p><p dir="RTL">من المُهِم التَّحكم في نوبات الصرع أثناء الحَمْل. مع ذلك، قد تكون هناك خطورة على طفلك إذا تناولتِ أدوية مضادة للصَّرَع أثناء الحَمْل.</p><p><u>عيوب خلقية</u></p><p>لم تظهر الدراسات زيادة في خطر الإصابة بعيوب خلقية التي ترتبط باستخدام عقار أوكسيكاربازيبين أثناء الحمل ، إلا أنه لا يمكن استبعاد خطر حدوث تشوهات خلقية لجنينك الذي لم يولد بعد.</p><p><u>&nbsp;</u></p><p><u>اضطرابات النمو العصبي</u></p><p dir="RTL">أظهرت بعض الدراسات أن التعرض لأوكسكاربازيبين في الرحم يؤثر بشكل سلبي على تطور وظائف المخ (النمو العصبي) عند الأطفال، بينما لم تجد دراسات أخرى مثل هذا التأثير. لا يمكن استبعاد إمكانية حدوث تأثير على النمو العصبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبركِ طبيبكِ بالفوائد والمخاطر المُحتَمَلة المتضمنة وسيُساعدكِ على اتخاذ قرار بشأن ما إذا كان عليكِ تناوُل عقار تريليبتال أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا توقفي علاجكِ بعقار تريليبتال أثناء الحَمْل دون الرجوع إلى طبيبكِ أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرَّضاعة الطبيعية</strong></p><p>إذا كنت تتناول هذا الدواء ، فاستشر طبيبك قبل البدء في الرضاعة الطبيعية. &nbsp;تمر المادة الفعَّالة في عقار تريليبتال إلى لبن الأم. وعلى الرغم من ذلك تشير المعلومات المتاحة الى ان كمية عقار تريبتال التي تنتقل للطفل الذي يرضع رضاعة طبيعية منخفضة. لا يمكن استبعاد خطر الأعراض الجانبية على الطفل.</p><p>سيناقش طبيبك معك حول الفوائد والمخاطر المحتملة للرضاعة الطبيعية أثناء تناول عقار تريبتال.&nbsp;</p><p dir="RTL">إذا كنتِ ترضعين أثناء تناولك لعقار تريبتال، وتعتقدين بأن طفلك يعاني من أعراض جانبية مثل النعاس المفرط أو ضعف في زيادة الوزن، أخبري طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. تأثير تريليبتال على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك عقار تريليبتال تشعر بالنُّعاس أو الدوخة، أو قد يُسبب لك عدم وضوح الرؤية أو ازدواج الرؤية أو عدم التَّناسق العضلي أو انخفاض مستوى الوعي، لا سيَّما عند بدء العلاج أو زيادة الجرعة.</p><p dir="RTL">من المُهِم المناقشة مع طبيبك بشأن ما إذا كان بإمكانك قيادة مركبة أو تشغيل آلات أثناء تناوُل هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناوَل دائمًا عقار تريليبتال كما أخبرك طبيبك أو الصيدلي الخاص بك بالضبط، حتى إذا كان ذلك يختلف عن المعلومات الواردة في هذه النَّشرة. يُرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التَّناول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ&zwnj;.ما كمية&nbsp; تريليبتال التي يجب استخدامها؟</strong></p><p dir="RTL"><strong>الجرعة بالنسبة للبالغين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جرعة البدء المُعتادة </strong>من عقار تريليبتال للبالغين (بما في ذلك المرضى من كبار السن) هي 600 مجم في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول قرصًا واحدًا 300 مجم مرتين يوميًّا أو قرصين 150 مجم مرتين يوميًّا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُزيد طبيبك الجرعة تدريجيًّا للتَّوصل إلى أفضل جرعة لحالتك. تكون أفضل النتائج عادةً مع الجرعات التي تتراوح بين 600 و2400 مجم في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت دواء آخر مضادًّا للصَّرَع، ستكون الجرعة هي نفسها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض كُلوي (مع قصور في وظائف الكُلى)، فستكون جرعة البدء نصف جرعة البدء المُعتادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمرض كبدي شديد، فقد يُعدِّل طبيبك جرعتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة بالنسبة للأطفال</strong></p><p dir="RTL">يُمكِن أن يتناول الأطفال بعُمْر 6 سنوات أو أكثر عقار تريليبتال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد الجرعة بالنسبة إلى الأطفال على أوزانهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح جرعة البدء بين 8 إلى 10 مللي جرام لكل كيلو جرام من وزن الجسم في اليوم تُعطى في جرعتين مُقسَّمتين. على سبيل المثال: سيبدأ الطفل الذي يبلغ وزنه 30 كجم العلاج بقرص واحد قدره 150 مجم مرتين يوميًّا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد طبيبك الجرعة تدريجيًّا للتَّوصل إلى أفضل جرعة بالنسبة لطفلك. تكون أفضل النتائج عادةً مع الجرعة التي قدرها 30 مللي جرام لكل كيلو جرام من وزن الجسم في اليوم. تبلغ الجرعة القصوى للطفل 46 مللي جرام لكل كيلو جرام من وزن الجسم في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينصح باستخدام تريليبتال للأطفال دون سن 6 سنوات لأنه لم يثبت أنه علاج آمن وفعال في هذه الفئة العمرية &quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية تناول عقار </strong><strong>تريليبتال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابْتَلِع الأقراص مع بعض الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا اقتضت الضَّرورة، يُمكِن تقسيم الأقراص إلى نصفين؛ للمساعدة على ابتلاعها.&nbsp; لا تقسم الأقراص بغرض الحصول على نصف الجرعة فقط. خط التَّقسيم ليس مُصَممًا لتقسيم القرص إلى جرعتين متساويتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للأطفال الصغار الذين لا يستطيعون ابتلاع الأقراص أو الذين لا يُمكِن إعطاؤهم الجرعة اللازمة في شكل قرص، يتوفر عقار تريليبتال في هيئة مُعَلَّق يستخدم عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى وكم من المدة يتم تناوُل عقار </strong><strong>تريليبتال</strong><strong>؟</strong></p><p dir="RTL">تناول عقار تريليبتال مرتين في اليوم، كل يوم، في الوقت نفسه تقريبًا من اليوم، ما لم يخبرك طبيبك بخلاف ذلك.&nbsp; سيكون لهذا أفضل تأثيرٍ على التحكم في الصرع.&nbsp; سيُساعِدك أيضًا في تذكر متى عليك تناوُل القرص (الأقراص).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك كم ستستمر مدة علاجك أو علاج طفلك بعقار تريليبتال. سيعتمد طول فترة العلاج على نوع النوبات التشنجية لديك أو لدى طفلك.&nbsp; قد يستلزم الأمر العلاج لعدة سنوات للتحكم في النوبات التشنجية. لا تغير الجرعة أو توقف العلاج دون التَّحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.الجرعة الزائدة من تريليبتال</strong></p><p dir="RTL">إذا تناولت كمية من الأقراص أكثر من التي وصفها لك طبيبك، فاتصل بأقرب مستشفى أو بطبيبك فورًا. قد تتضمن أعراض الجرعة الزَّائدة من عقار تريليبتال ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نُعاس، دوخة، مشاكل في تنسيق الحركة و/ أو حركة لا إرادية بالعينين، انتفاضًا عضليًّا أو تفاقمًا ملحوظًا للتشنجات، صداع، فقدان الوعي، غيبوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (الغثيان)، أو إعياء (القيء)، أو زيادة الحركات غير المنضبطة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خمولًا، ازدواج الرؤية، تضيُّق الجزء الأسود من العين، عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التَّنفس وضحالته (انخفاض معدل التنفس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب (إطالة فترة &quot;QTc&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش، صداع، غيبوبة، انخفاض الوعي، حركات بالفم واللسان والأطراف لا يُمكِن السيطرة عليها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوانية، هيجان، ارتباك/ التباس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>عُسْر التَّنَفُّس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. نسيان تناول جرعة من تريليبتال</strong></p><p dir="RTL">إذا أغفلت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. مع ذلك، إذا حان موعد جرعتك التَّالية، فلا تتناول الجرعة التي أغفلتها. ثم عُد إلى جدول مواعيد الجرعات المُعتاد الخاص بك. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا أو قد أغفلت تناوُل جرعات متعددة، فاتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">د. التوقف عن تناول تريليبتال</p><p dir="RTL">لا تتوقف عن تناول دوائك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمنع حدوث تفاقم مفاجئ للنوبات التشنُّجية التي تعاني منها، لا توقف دواءك بشكل مفاجئ أبدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم إيقاف علاجك، فلا بد أن يتم ذلك بشكل تدريجي وفقًا لتعليمات طبيبك.</p><p dir="RTL">&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>أخبر طبيبك على الفور، أو اذهب لقسم الطوارئ بأقرب مستشفى إليك إذا أُصبت بأي من الآثار الجانبية التَّالية:</em></strong></p><p dir="RTL">فيما يلي علامات لآثار جانبية نادرة جدًّا ولكنها قد تكون خطيرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000&nbsp;شخص)، والتي قد تحتاج إلى العلاج الطبي العاجل. سيقرر الطبيب أيضًا ما إذا كان يجب إيقاف العلاج بعقار تريليبتال فورًا وكيفية الاستمرار في تلقي المزيد من الرعاية الطبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الشفتين، الجفون، الوجه، الحَلْق أو الفم، مصحوب بصعوبة في التَّنفس أو التكلم أو البلع (علامات حدوث رد الفعل التحسسي ووذمة وعائية) أو علامات أخرى لتفاعلات فرط الحساسية مثل: الطفح الجلدي والحُمّى وألم في العضلات والمفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بثور شديدة على الجلد و/ أو الأغشية المخاطية للشفتين أو العينين أو الفم أو الممرات الأنفية أو الأعضاء التناسلية (علامات الإصابة بتفاعلات حساسية خطيرة تشمل متلازمة لايل ومتلازمة ستيفنز جونسون والاحمرار متعدد الأشكال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب، ضيق التَّنفس عند ممارسة التمارين الرياضية، شحوب، صداع، قشعريرة، دوخة، عدوى متكررة تُؤدي إلى حدوث حُمّى، التهاب الحَلْق، قُرَح الفم، حدوث نزيف أو كدمات بصورة أسهل من المُعتاد، نزيف من الأنف، ظهور بقع حمراء أو أرجوانية أو ظهور بقع على الجلد ليس لها مبرر (علامات حدوث انخفاض في عدد الصفائح الدَّموية بالدم أو انخفاض في عدد خلايا الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بقعي أحمر يحدث بشكل أساسي على الوجه قد يُصاحِبه إرهاق، حُمّى، شعور بالإعياء (غثيان) أو فقدان الشهية (علامات الذئبة الحمامية الجهازية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خمول، ارتباك/ التباس، انتفاض عضلي أو تفاقم ملحوظ للتشنجات (أعراض مُحتَمَلة على انخفاض مستويات الصوديوم في الدَّم) (انظر: قسم 2 فقرة ب&zwnj;:الاحتياطات عند استعمال تريليبتال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بأعراض الأنفلونزا مع يرقان (اصفرار الجلد أو بياض العينين) (علامات الإصابة بالتهاب كبدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بالجزء العلوي من المعدة (البطن)، إعياء (قيء)، فقدان الشهية (علامات الإصابة بالتهاب البنكرياس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن، تعب، تساقط الشَّعر، ضعف العضلات، الشعور بالبرد (علامات على ضعف نشاط الغدة الدَّرقية).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك بأسرع ما يُمكِن إذا أُصِبت بأي من الآثار الجانبية التَّالية، </strong>فقد تستلزم العناية الطبية:</p><p dir="RTL"><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف، مشاكل في التَّنسيق، حركات غير إرادية بالعينين، قلق وعصبية، اكتئاب، تقلب الحالة المزاجية، طفح جلدي.</p><p dir="RTL"><strong>نادرة جدًّا </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب أو مُعدَّل سريع جدًّا أو بطيء جدًّا لضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى <em>التي قد تحدث</em>: </strong></p><p dir="RTL">وتكون تلك عادةً آثارًا جانبية طفيفة إلى معتدلة لعقار تريليبتال.&nbsp; غالبية هذه الآثار تكون عابرة وتقل عادةً بمرور الوقت.</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب، صداع، دوخة، نعاس، شعور بالإعياء (غثيان)، إعياء (قيء)، ازدواج الرؤية.</p><p dir="RTL"><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف، اضطرابات الذَّاكرة، ضعف التركيز، لا مبالاة، هِياج، ارتباك/ التباس، عدم وضوح الرؤية، اضطرابات الرؤية، إمساك، إسهال، ألم بالمعدة (بالبطن)، حب الشباب، تساقط الشعر، اضطرابات التَّوازن، زيادة الوزن.</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (أرتكاريا). قد تتعرَّض أيضًا لارتفاع مستويات إنزيمات الكبد أثناء تناوُل عقار تريليبتال.</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم، اضطراب بالكلام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وردت تقارير عن حدوث اضطرابات بالعظام وتشمل انخفاض كثافة العظام وهشاشة العظام (ترقق العظام) وكسور العظام.&nbsp; راجع طبيبك أو الصيدلي الخاص بك إذا كنت تتناول علاجًا طويل الأمد مضادًّا للصَّرع أو كان لديك تاريخ مَرَضي من الإصابة بهشاشة العظام أو إذا كنت تتناول الستيرويدات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض هرمون الغدة الدرقية في الدم ، ينظر في اختبار وظائف الغدة الدرقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط</p><p>الجلد الأحمر المتورم مع وجود بقع صغيرة مملوءة بالقيح &nbsp;)العمى الحاد الناجم عن التهاب الغدد الصماء الحاد</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يخزن في درجة حرارة أعلى من ٣٠ درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الشريط والعبوة الكرتونية الخارجية.&nbsp; يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدَّواء إذا لاحظت أنَّ العبوة تالفة أو يبدو عليها علامات العبث.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة بعقار تريليبتال هي أوكسكاربازيبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار تريليبتال 150 مجم أقراص مغلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص مغلف على 150 مجم أوكسكاربازيبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار تريليبتال 300 مجم أقراص مغلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص مغلف على 300 مجم أوكسكاربازيبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار تريليبتال 600 مجم أقراص مغلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص مغلف على 600 مجم أوكسكاربازيبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><strong>محتوى القرص الدَّاخلي:</strong> سيليكا غروية لا مائية، سليلوز دقيق التبلور، هيبروميلوز، كروسبوفيدون، ستيرات الماغنسيوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الغلاف الخارجي للقرص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القرص المحتوي على <strong>150 مجم</strong>: هيبروميلوز، ماكروجول 4000، أكسيد الحديد الأصفر (E 172)، أكسيد الحديد الأحمر (E&nbsp;172)، أكسيد الحديد الأسود (E 172)، تلك، ثاني أكسيد التيتانيوم (E 171).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القرص المحتوي على <strong>300 مجم</strong>: هيبروميلوز، ماكروجول 8000، أكسيد الحديد الأصفر (E 172)، تلك، ثاني أكسيد التيتانيوم (E 171).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القرص المحتوي على <strong>600 مجم</strong>: هيبروميلوز، ماكروجول 4000، أكسيد الحديد الأحمر (E 172)، أكسيد الحديد الأسود (E&nbsp;172)، تلك، ثاني أكسيد التيتانيوم (E 171).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">تكون الأقراص المغلفة لعقار تريليبتال 150 مجم ذات لون أخضر رمادي شاحب، بيضاوية الشكل، محززة على كلا&nbsp; الجانبين ومنقوشًا على أحد جانبيها T/D وعلى الجانب الآخر C/G.</p><p dir="RTL" style="text-align:justify"><em>&nbsp;</em></p><p dir="RTL" style="text-align:justify">تكون الأقراص المغلفة لعقار تريليبتال 300 مجم ذات لون أصفر، بيضاوية الشكل، محززة على كلا الجانبين ومنقوشًا على أحد جانبيها TE/TE وعلى الجانب الآخر CG/CG.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify">تكون الأقراص المغلفة لعقار تريليبتال 600 مجم ذات لون وردي فاتح، بيضاوية الشكل، محززة على كلا الجانبين ومنقوشًا على أحد جانبيها TF/TF وعلى الجانب الآخر CG/CG.</p><p dir="RTL" style="text-align:justify"><em>&nbsp;</em></p><p dir="RTL" style="text-align:justify">يتوفر عقار تريليبتال أقراص مغلَّفة في عبوات شرائط بها 30، 50، 100، 200، و500 قرص.</p><p dir="RTL" style="text-align:justify"><s>&nbsp;</s></p><p dir="RTL" style="text-align:justify">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د‌.	تم اعتماد هذه النَّشرة من قبل المملكة المتحدة في مايو2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trileptal 150 mg Film-coated Tablets
Oxcarbazepine 150 mg Film-coated Tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 150 mg of oxcarbazepine.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

Pale grey green, ovaloid slightly biconvex tablets, scored on both sides. Embossed with T/D on one side and C/G on the other side.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trileptal is indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures.</p><p>&nbsp;</p><p>Trileptal is indicated for use as monotherapy or adjunctive therapy in adults and in children of 6 years of age and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>In mono- and adjunctive therapy, treatment with Trileptal is initiated with a clinically effective dose given in two divided doses. The dose may be increased depending on the clinical response of the patient. When other antiepileptic medicinal products are replaced by Trileptal, the dose of the concomitant antiepileptic medicinal product(s) should be reduced gradually on initiation of Trileptal therapy. In adjunctive therapy, as the total antiepileptic medicinal product load of the patient is increased, the dose of concomitant antiepileptic medicinal product(s) may need to be reduced and/or the Trileptal dose increased more slowly (see section 4.5).</p><p>&nbsp;</p><p><strong>Therapeutic drug monitoring</strong></p><p>The therapeutic effect of oxcarbazepine is primarily exerted through the active metabolite 10-monohydroxy derivative (MHD) of oxcarbazepine (see section 5).</p><p>&nbsp;</p><p>Plasma level monitoring of oxcarbazepine or MHD is not routinely warranted. However, may be useful in situations where an alteration in MHD clearance is to be expected (see section 4.4). In such situations, the dose of Trileptal may be adjusted (based on plasma levels measured 2-4 hours post dose) to maintain peak MHD plasma levels &lt; 35 mg/L.</p><p>&nbsp;</p><p><u>Adults</u></p><p><u>&nbsp;</u></p><p><em>Monotherapy</em></p><p><strong>Recommended initial dose</strong></p><p>Trileptal should be initiated with a dose of 600&nbsp;mg/day (8-10&nbsp;mg/kg/day) given in 2 divided doses.</p><p>&nbsp;</p><p><strong>Maintenance dose</strong></p><p>If clinically indicated, the dose may be increased by a maximum of 600&nbsp;mg/day at approximately weekly intervals from the starting dose to achieve the desired clinical response<em>.</em></p><p>&nbsp;</p><p>Therapeutic effects are seen at doses between 600&nbsp;mg/day and 2,400&nbsp;mg/day.</p><p>&nbsp;</p><p>Controlled monotherapy trials in patients not currently being treated with antiepileptic medicinal products showed 1,200&nbsp;mg/day to be an effective dose; however, a dose of 2,400&nbsp;mg/day has been shown to be effective in more refractory patients converted from other antiepileptic medicinal products to Trileptal monotherapy.</p><p>&nbsp;</p><p><strong>Maximum recommended dose</strong></p><p>In a controlled hospital setting, dose increases up to 2,400&nbsp;mg/day have been achieved over 48&nbsp;hours.</p><p>&nbsp;</p><p><em>Adjunctive therapy</em></p><p><strong>Recommended initial dose</strong></p><p>Trileptal should be initiated with a dose of 600&nbsp;mg/day (8-10&nbsp;mg/kg/day) given in 2 divided doses.</p><p>&nbsp;</p><p><strong>Maintenance dose</strong></p><p>If clinically indicated, the dose may be increased by a maximum of 600&nbsp;mg/day at approximately weekly intervals from the starting dose to achieve the desired clinical response.</p><p>&nbsp;</p><p>Therapeutic responses are seen at doses between 600&nbsp;mg/day and 2,400&nbsp;mg/day.</p><p>&nbsp;</p><p><strong>Maximum recommended dose</strong></p><p>Daily doses from 600 to 2,400&nbsp;mg/day have been shown to be effective in a controlled adjunctive therapy trial, although most patients were not able to tolerate the 2,400&nbsp;mg/day dose without reduction of concomitant antiepileptic medicinal products, mainly because of CNS-related adverse events. Daily doses above 2,400&nbsp;mg/day have not been studied systematically in clinical trials.</p><p>&nbsp;</p><p><u>Elderly (65 years old and above) </u></p><p>No special dose recommendations are necessary in elderly patients because therapeutic doses are individually adjusted. Dosage adjustments are recommended in elderly patients with renal impairment (creatinine clearance less than 30 ml/min) (see information below on dosage in renal impairment).</p><p>Close monitoring of sodium levels is required in patients at risk of hyponatremia (see section 4.4).</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>No dosage adjustment is required for patients with mild to moderate hepatic impairment. Trileptal has not been studied in patients with severe hepatic impairment, therefore, caution should be exercised when dosing severely impaired patients (see section 5.2).</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>In patients with impaired renal function (creatinine clearance less than 30&nbsp;ml/min) Trileptal therapy should be initiated at half the usual starting dose (300&nbsp;mg/day) and increased, in at least weekly intervals, to achieve the desired clinical response<strong> </strong>(see section 5.2).</p><p>Dose escalation in renally impaired patients may require more careful observation.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><strong>&nbsp;</strong></p><p><strong>Recommended initial dose</strong></p><p>In mono- and adjunctive therapy, Trileptal should be initiated with a dose of 8-10&nbsp;mg/kg/day given in 2 divided doses.</p><p>&nbsp;</p><p><strong>Maintenance dose </strong></p><p>In adjunctive therapy trials, a maintenance dose of 30-46 mg/kg/day, achieved over two weeks, is shown to be effective and well tolerated in children.<em> </em>Therapeutic effects were seen at a median maintenance dose of approximately 30&nbsp;mg/kg/day.</p><p>&nbsp;</p><p><strong>Maximum recommended dose</strong></p><p>If clinically indicated, the dose may be increased by a maximum of 10&nbsp;mg/kg/day at approximately weekly intervals from the starting dose, to a maximum dose of 46&nbsp;mg/kg/day, to achieve the desired clinical response (see section 5.2).</p><p>&nbsp;</p><p>Trileptal is recommended for use in children of 6 years of age and above. Safety and efficacy have been evaluated in controlled clinical trials involving approximately 230 children aged less than 6 years (down to 1 month). Trileptal is not recommended in children aged less than 6 years since safety and efficacy have not been adequately demonstrated.</p><p>&nbsp;</p><p>All the above dosing recommendations (adults, elderly and children) are based on the doses studied in clinical trials for all age groups. However, lower initiation doses may be considered where appropriate.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Method of administration</u></strong></p><p>The tablets are scored and can be broken into two halves in order to make it easier for the patient to swallow the tablet. However, the tablet cannot be divided into equal doses. For children, who cannot swallow tablets or where the required dose cannot be administered using tablets, a Trileptal oral suspension is available.</p><p>Trileptal can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to eslicarbazepine or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Class I (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been received in the post-marketing period. Cases of anaphylaxis and angioedema involving the larynx, glottis, lips and eyelids have been reported in patients after taking the first or subsequent doses of Trileptal. If a patient develops these reactions after treatment with Trileptal, the drug should be discontinued and an alternative treatment started.</p><p>&nbsp;</p><p>Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that approximately 25-30&nbsp;% of these patients may experience hypersensitivity reactions (e.g. severe skin reactions) with Trileptal (see section 4.8).</p><p>&nbsp;</p><p>Hypersensitivity reactions, including multi-organ hypersensitivity reactions, may also occur in patients without a history of hypersensitivity to carbamazepine. Such reactions can affect the skin, liver, blood and lymphatic system or other organs, either individually or together in the context of a systemic reaction (see section 4.8). In general, if signs and symptoms suggestive of hypersensitivity reactions occur, Trileptal should be withdrawn immediately.</p><p>&nbsp;</p><p><u>Dermatological effects</u></p><p>Serious dermatological reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&rsquo;s syndrome) and erythema multiforme, have been reported very rarely in association with the use of Trileptal. Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and very rarely be fatal. Trileptal associated cases occurred in both children and adults. The median time to onset was 19 days. Several isolated cases of recurrence of the serious skin reaction when rechallenged with Trileptal were reported. Patients who develop a skin reaction with Trileptal should be promptly evaluated and Trileptal withdrawn immediately unless the rash is clearly not drug related. In case of treatment withdrawal, consideration should be given to replacing Trileptal with other antiepileptic drug therapy to avoid withdrawal seizures. Trileptal should not be restarted in patients who discontinued treatment due to a hypersensitivity reaction (see section 4.3).</p><p>&nbsp;</p><p><u>HLA-B*1502 allele &ndash; in Han Chinese, Thai and other Asian populations </u></p><p>HLA-B*1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing the severe cutaneous reactions known as Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) when treated with carbamazepine. The chemical structure of oxcarbazepine is similar to that of carbamazepine, and it is possible that patients who are positive for HLA‐B*1502 may also be at risk for SJS/TEN after treatment with oxcarbazepine. There are some data that suggest that such an association exists for oxcarbazepine. The prevalence of HLA-B*1502 carrier is about 10% in Han Chinese and Thai populations. Whenever possible, these individuals should be screened for this allele before starting treatment with carbamazepine or<u> </u>a chemically-related active substance. If patients of these origins are tested positive for HLA‐B*1502 allele, the use of oxcarbazepine may be considered if the benefits are thought to exceed risks.</p><p>&nbsp;</p><p>Because of the prevalence of this allele in other Asian populations (e.g. above 15% in the Philippines and Malaysia), testing genetically at risk populations for the presence of HLA-B*1502 may be considered.</p><p>The prevalence of the HLA-B*1502 allele is negligible in e.g. European descent, African, Hispanic populations sampled, and in Japanese and Koreans (&lt; 1%).</p><p>&nbsp;</p><p>Allele frequencies refer to the percentage of chromosomes in the population that carry a given allele.&nbsp; Since a person carries two copies of each chromosome, but even one copy of the HLA-B*1502 allele may be enough to increase the risk of SJS, the percentage of patients who may be at risk is nearly twice the allele frequency.</p><p>&nbsp;</p><p><u>HLA-A*3101 allele &ndash; European descent and Japanese populations </u></p><p>There are some data that suggest HLA-A*3101 is associated with an increased risk of carbamazepine induced cutaneous adverse reactions including SJS, TEN, Drug rash with eosinophilia (DRESS), or less severe acute generalized exanthematous pustulosis (AGEP) and maculopapular rash in people of European descent and the Japanese.</p><p>&nbsp;</p><p>The frequency of the HLA-A*3101 allele varies widely between ethnic populations. HLA-A*3101 allele has a prevalence of 2 to 5% in European populations and about 10% in Japanese population.</p><p>The presence of HLA-A*3101 allele may increase the risk for carbamazepine induced cutaneous reactions (mostly less severe) from 5.0% in general population to 26.0% among subjects of European ancestry, whereas its absence may reduce the risk from 5.0% to 3.8%.</p><p>&nbsp;</p><p><u>HLA-A*3101 allele &ndash; Other descents</u></p><p>The frequency of this allele is estimated to be less than 5% in the majority of Australian, Asian, African and North American populations with some exceptions within 5 to 12%. Frequency above 15% has been estimated in some ethnic groups in South America (Argentina and Brazil), North America (US Navajo and Sioux, and Mexico Sonora Seri) and Southern India (Tamil Nadu) and between 10% to 15% in other native ethnicities in these same regions.</p><p>&nbsp;</p><p>Allele frequencies refer to the percentage of chromosomes in the population that carry a given allele.&nbsp; Since a person carries two copies of each chromosome, but even one copy of the HLA-A*3101 allele may be enough to increase the risk of SJS, the percentage of patients who may be at risk is nearly twice the allele frequency.</p><p>&nbsp;</p><p>There are insufficient data supporting a recommendation for HLA-A*3101 screening before starting carbamazepine or chemically-related compounds treatment.</p><p>&nbsp;</p><p>If patients of European descent or Japanese origin are known to be positive for HLA-A*3101 allele, the use of carbamazepine or chemically-related compounds may be considered if the benefits are thought to exceed risks.</p><p>&nbsp;</p><p><u>Limitation of genetic screening </u></p><p>Genetic screening results must never substitute appropriate clinical vigilance and patient management. Many Asian patients positive for HLA-B*1502 and treated with Trileptal will not develop SJS/TEN, and patients negative for HLA-B*1502 of any ethnicity can still develop SJS/TEN. The same is true for HLA-A*3101 with respect to risk of SJS, TEN, DRESS, AGEP or maculopapular rash. The development of these severe cutaneous adverse reactions and its related morbidity due to other possible factors such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.</p><p>&nbsp;</p><p><u>Information for healthcare professionals </u></p><p>If testing for the presence of the HLA-B*1502 allele is performed, high-resolution &ldquo;HLA-B*1502 genotyping&rdquo; is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected, and negative if no HLA-B*1502 alleles are detected. Similarly, if testing for the presence of the HLA-A*3101 allele is performed, high resolution &ldquo;HLA-A*3101 genotyping&rdquo; is recommended. The test is positive if either one or two HLA-A*3101 alleles are detected, and negative if no HLA-A*3101 alleles are detected.</p><p>&nbsp;</p><p><u>Risk of seizure aggravation </u></p><p>Risk of seizure aggravation has been reported with Trileptal. The risk of seizure aggravation is seen especially in children but may also occur in adults. In case of seizure aggravation, Trileptal should be discontinued.</p><p>&nbsp;</p><p><u>Hyponatraemia</u></p><p>Serum sodium levels below 125&nbsp;mmol/l, usually asymptomatic and not requiring adjustment of therapy, have been observed in up to 2.7&nbsp;% of Trileptal treated patients. Experience from clinical trials shows that serum sodium levels returned towards normal when the Trileptal dosage was reduced, discontinued or the patient was treated conservatively<em> </em>(e.g. restricted fluid intake). In patients with pre-existing renal conditions associated with low sodium levels (e.g. inappropriate ADH secretion like syndrome) or in patients treated concomitantly with sodium-lowering medicinal products (e.g. diuretics, desmopressin) as well as NSAIDs (e.g. indometacin), serum sodium levels should be measured prior to initiating therapy. Thereafter, serum sodium levels should be measured after approximately two weeks and then at monthly intervals for the first three months during therapy, or according to clinical need. These risk factors may apply especially to elderly patients. For patients on Trileptal therapy when starting on sodium-lowering medicinal products, the same approach for sodium checks should be followed. In general, if clinical symptoms suggestive of hyponatraemia occur on Trileptal therapy (see section 4.8), serum sodium measurement may be considered. Other patients may have serum sodium levels assessed as part of their routine laboratory studies.</p><p>&nbsp;</p><p>All patients with cardiac insufficiency and secondary heart failure should have regular weight measurements to determine occurrence of fluid retention. In case of fluid retention or worsening of the cardiac condition, serum sodium levels should be checked. If hyponatraemia is observed, water restriction is an important counter-measurement. As oxcarbazepine may, very rarely, lead to impairment of cardiac conduction, patients with pre-existing conduction disturbances (e.g. atrioventricular-block, arrhythmia) should be followed carefully.</p><p>&nbsp;</p><p><u>Hypothyroidism </u></p><p>Hypothyroidism is an adverse reaction (with &ldquo;not known&rdquo; frequency, see section 4.8) of oxcarbazepine. Considering the importance of thyroid hormones in children&rsquo;s development after birth, thyroid function monitoring is recommended in the pediatric age group while on Trileptal therapy.</p><p>&nbsp;</p><p><u>Hepatic function</u></p><p>Very rare cases of hepatitis have been reported, which in most cases resolved favourably. When a hepatic event is suspected, liver function should be evaluated and discontinuation of Trileptal should be considered. Caution should be exercised when treating patients with severe hepatic impairment (see section 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Renal function </u></p><p>In patients with impaired renal function (creatinine clearance less than 30 mL/min), caution should be exercised during Trileptal treatment especially with regard to the starting dose and up titration of the dose. Plasma level monitoring of MHD may be considered (see section 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Hematological effects</u></p><p>Very rare reports of agranulocytosis, aplastic anemia and pancytopenia have been seen in patients treated with Trileptal during post-marketing experience (see section 4.8).</p><p>&nbsp;</p><p>Discontinuation of the medicinal product should be considered if any evidence of significant bone marrow depression develops.</p><p>&nbsp;</p><p><u>Suicidal behaviour</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomized placebo controlled trials of antiepileptic medicines has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for oxcarbazepine.</p><p>&nbsp;</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>&nbsp;</p><p><u>Hormonal contraceptives</u></p><p>Female patients of childbearing age should be warned that the concurrent use of Trileptal with hormonal contraceptives may render this type of contraceptive ineffective (see section 4.5). Additional non-hormonal forms of contraception are recommended when using Trileptal.</p><p>&nbsp;</p><p><u>Alcohol</u></p><p>Caution should be exercised if alcohol is taken in combination with Trileptal therapy, due to a possible additive sedative effect.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Withdrawal</u></p><p>As with all antiepileptic medicinal products, Trileptal should be withdrawn gradually to minimise the potential of increased seizure frequency.</p><p>&nbsp;</p><p><u>Monitoring of plasma levels</u></p><p>Although correlations between dosage and plasma levels of oxcarbazepine, and between plasma levels and clinical efficacy or tolerability are rather tenuous, monitoring of the plasma levels may be useful in the following situations in order to rule out noncompliance or in situations where an alteration in MHD clearance is to be expected, including:</p><ul><li>changes in renal function (see renal impairment in section 4.2).</li><li>pregnancy (see section 4.6 and 5).</li><li>concomitant use of liver enzyme-inducing medicines (see section 4.5).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Enzyme induction</u></p><p>Oxcarbazepine and its pharmacologically active metabolite (the monohydroxy derivative, MHD)<em> </em>are weak inducers <em>in vitro</em> and <em>in vivo</em> of the cytochrome P450 enzymes CYP3A4 and CYP3A5 responsible for the metabolism of a very large number of medicines, for example, immunosuppressants (e.g. ciclosporin, tacrolimus), oral contraceptives (see below), and some other antiepileptic medicinal products (e.g. carbamazepine) resulting in a lower plasma concentration of these medicinal products (see table below summarizing results with other antiepileptic medicinal products).</p><p>&nbsp;</p><p><em>In vitro</em>, oxcarbazepine and MHD are weak inducers of UDP-glucuronyl transferases (effects on specific enzymes in this family are not known). Therefore, <em>in vivo</em> oxcarbazepine and MHD may have a small inducing effect on the metabolism of medicinal products which are mainly eliminated by conjugation through the UDP-glucuronyl transferases. When initiating treatment with Trileptal or changing the dose, it may take 2 to 3 weeks to reach the new level of induction.</p><p>&nbsp;</p><p>In case of discontinuation of Trileptal therapy, a dose reduction of the concomitant medications may be necessary and should be decided upon by clinical and/or plasma level monitoring. The induction is likely to gradually decrease over 2 to 3 weeks after discontinuation.</p><p>&nbsp;</p><p>Hormonal contraceptives: Trileptal was shown to have an influence on the two components, ethinylestradiol (EE) and levonorgestrel (LNG), of an oral contraceptive. The mean AUC values of EE and LNG were decreased by 48-52 % and 32-52% respectively. Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives ineffective (see section 4.4). Another reliable contraceptive method should be used.</p><p>&nbsp;</p><p><u>Enzyme inhibition</u></p><p>Oxcarbazepine and MHD inhibit CYP2C19. Therefore, interactions could arise when co-administering high doses of Trileptal with medicinal products that are mainly metabolised by CYP2C19 (e.g. phenytoin). Phenytoin plasma levels increased by up to 40 % when Trileptal was given at doses above 1,200 mg/day (see table below summarizing results with other anticonvulsants). In this case, a reduction of co-administered phenytoin may be required (see section 4.2).</p><p>&nbsp;</p><p><u>Antiepileptic and enzyme inducing medicinal products</u></p><p>Potential interactions between Trileptal and other antiepileptic medicinal products were assessed in clinical studies. The effect of these interactions on mean AUCs and C<sub>min</sub> are summarised in the following table.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Summary of antiepileptic medicinal product interactions with Trileptal</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Antiepileptic medicinal product</p></td><td style="vertical-align:top"><p>Influence of Trileptal on antiepileptic medicinal product</p></td><td style="vertical-align:top"><p>Influence of antiepileptic medicinal product on MHD</p></td></tr><tr><td style="vertical-align:top"><p>Co-administered</p></td><td style="vertical-align:top"><p>Concentration</p></td><td style="vertical-align:top"><p>Concentration</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>0&nbsp;-&nbsp;22&nbsp;% decrease<br />(30&nbsp;% increase of carbamazepine-epoxide)</p></td><td style="vertical-align:top"><p>40&nbsp;% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Clobazam</p></td><td style="vertical-align:top"><p>Not studied</p></td><td style="vertical-align:top"><p>No influence</p></td></tr><tr><td style="vertical-align:top"><p>Felbamate</p></td><td style="vertical-align:top"><p>Not studied</p></td><td style="vertical-align:top"><p>No influence</p></td></tr><tr><td style="vertical-align:top"><p>Lamotrigine</p></td><td style="vertical-align:top"><p>No influence</p></td><td style="vertical-align:top"><p>No influence</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbitone</p></td><td style="vertical-align:top"><p>14&nbsp;-&nbsp;15&nbsp;% increase</p></td><td style="vertical-align:top"><p>30&nbsp;-&nbsp;31&nbsp;% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>0&nbsp;-&nbsp;40&nbsp;% increase</p></td><td style="vertical-align:top"><p>29&nbsp;-&nbsp;35&nbsp;% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Valproic acid</p></td><td style="vertical-align:top"><p>No influence</p></td><td style="vertical-align:top"><p>0&nbsp;&ndash;&nbsp;18&nbsp;% decrease</p></td></tr></tbody></table><p>&nbsp;</p><p>Strong inducers of cytochrome P450 enzymes and/or UGT (i.e. rifampicin, carbamazepine, phenytoin and phenobarbitone) have been shown to decrease the plasma/serum levels of MHD (29-49&nbsp;%) in adults; in children 4 to 12 years of age, MHD clearance increased by approximately 35% when given one of the three enzyme-inducing antiepileptic medicinal products compared to monotherapy. Concomitant therapy of Trileptal and lamotrigine has been associated with an increased risk of adverse events (nausea, somnolence, dizziness and headache). When one or several antiepileptic medicinal products are concurrently administered with Trileptal, a careful dose adjustment and/or plasma level monitoring may be considered on a case by case basis,<strong><em> </em></strong>notably in paediatric patients treated concomitantly with lamotrigine.</p><p>&nbsp;</p><p>No autoinduction has been observed with Trileptal.</p><p><em>&nbsp;</em></p><p><u>Other medicinal product interactions</u></p><p>Cimetidine, erythromycin, viloxazine, warfarin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.</p><p>&nbsp;</p><p>The interaction between oxcarbazepine and MAOIs is theoretically possible based on a structural relationship of oxcarbazepine to tricyclic antidepressants.</p><p>&nbsp;</p><p>Patients on tricyclic antidepressant therapy were included in clinical trials and no clinically relevant interactions have been observed.</p><p>&nbsp;</p><p>The combination of lithium and oxcarbazepine might cause enhanced neurotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential and contraceptive measures </u></p><p>Trileptal may result in a failure of the therapeutic effect of oral contraceptive medicines containing ethinylestradiol (EE) and levonorgestrel (LNG) (see section 4.4 and 4.5). Women of child bearing potential should be advised to use highly effective contraception (preferably non-hormonal; e.g. intrauterine implants) while on treatment with Trileptal.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><em>Risk related to epilepsy and antiepileptic medicinal products in general:</em></p><p>In the treated population, an increase in malformations has been noted with polytherapy, particularly in polytherapy including valproate.</p><p>&nbsp;</p><p>Moreover, effective anti-epileptic therapy must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.</p><p>&nbsp;</p><p><em>Risk related to oxcarbazepine:</em></p><p>There is moderate amount of data on pregnant women (300-1000 pregnancy outcomes). However, the data on oxcarbazepine associated with congenital malformation is limited. There is no increase in the total rate of malformations with Trileptal as compared with the rate observed in the general population (2-3%). Nevertheless, with this amount of data, a moderate teratogenic risk cannot be completely excluded. .<strong><u> Study results related to the risk of neurodevelopmental disorders in children exposed to oxcarbazepine during pregnancy are conflicting and a risk cannot be excluded.</u></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Taking these data into consideration:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If women receiving Trileptal become pregnant or plan to become pregnant, the use of this product should be carefully re-evaluated. Minimum effective doses should be given, and monotherapy whenever possible should be preferred at least during the first three months of pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During pregnancy, an effective antiepileptic oxcarbazepine treatment must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.</p><p>&nbsp;</p><p><em>Monitoring and prevention:</em></p><p>Some antiepileptic medicinal products may contribute to folic acid deficiency, a possible contributory cause of foetal abnormality. Folic acid supplementation is recommended before and during pregnancy. As the efficacy of this supplementation is not proved, a specific antenatal diagnosis should be offered even for women with a supplementary treatment of folic acid.</p><p>&nbsp;</p><p>Data from a limited number of women indicate that plasma levels of the active metabolite of oxcarbazepine, the 10-monohydroxy derivative (MHD), may gradually decrease throughout pregnancy. It is recommended that clinical response should be monitored carefully in women receiving Trileptal treatment during pregnancy to ensure that adequate seizure control is maintained. Determination of changes in MHD plasma concentrations should be considered. If dosages have been increased during pregnancy, postpartum MHD plasma levels may also be considered for monitoring.</p><p><em>&nbsp;</em></p><p><em>In the newborn child:</em></p><p>Bleeding disorders in the newborn have been reported with hepatic inductor antiepileptic medicines. As a precaution, vitamin K<sub>1</sub> should be administered as a preventive measure in the last few weeks of pregnancy and to the newborn.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Oxcarbazepine and its active metabolite (MHD) are excreted in human breast milk. <strong><u>Limited data indicate that the breastfed infants&acute;MHD plasma concentrations are 0.2-0.8 &micro;g/ml, corresponding to up to 5% of the maternal MHD plasma concentration. Although exposure appears to be low, a risk to the infant cannot be excluded. Therefore, a decision whether to breastfeed while using [Trileptal]</u></strong>[RSK1]&nbsp;<strong><u> should take into consideration both the benefit of breastfeeding and the potential risk of side effects in the infant. If breastfed, the infant should be monitored for adverse effects such as drowsiness and poor weight gain.</u></strong></p><p>&nbsp;</p><p>&nbsp;</p><p><u>Fertility </u></p><p>There are no human data on fertility.</p><p>In rats, oxcarbazepine had no effects on fertility. Effects on reproductive parameters in female rats were observed for MHD at doses comparable to those in humans (see section 5.3).</p><p>&nbsp;[RSK1]Replace [product name] with Trileptal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions such as dizziness, somnolence, ataxia, diplopia, blurred vision, visual disturbances, hyponatremia and depressed level of consciousness were reported with Trileptal (for complete list of ADRs see section 4.8), especially at the start of treatment or in connection with dose adjustments (more frequently during the up titration phase). Patients should therefore exercise due caution when driving a vehicle or operating machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a.Summary of the safety profile</u></p><p>The most commonly reported adverse reactions are somnolence, headache, dizziness, diplopia, nausea, vomiting and fatigue occurring in more than 10% of patients.</p><p>&nbsp;</p><p>The safety profile is based on adverse events from clinical trials assessed as related to Trileptal. In addition, clinically meaningful reports on adverse experiences from named patient programs and postmarketing experience were taken into account.</p><p>&nbsp;</p><p>Adverse reactions (Table 1) are listed by MedRA system organ class.</p><p>Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category, using the following convention (CIOMS III) is also provided for each adverse reaction: very common (&sup3;&nbsp;1/10); common (&sup3;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10); uncommon (&sup3;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100); rare (&sup3; 1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><u>Table 1&nbsp; Adverse reactions</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>leucopenia.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>thrombocytopenia.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>bone marrow depression, aplastic anemia, agranulocytosis, pancytopenia, neutropenia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>hypersensitivity<strong><sup>#</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Not known</p></td><td style="vertical-align:top"><p>weight increased.</p><p>hypothyroidism.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hyponatraemia<sup>&dagger;</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Inappropriate ADH secretion like syndrome with signs and symptoms of lethargy, nausea, dizziness, decrease in serum (blood) osmolality, vomiting, headache, confusional state or other neurological signs and symptoms.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>agitation (e.g. nervousness), affect lability, confusional state, depression, apathy.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>somnolence, headache, dizziness.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>ataxia, tremor, nystagmus, disturbance in attention, amnesia.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Speech disorders (including dysarthria); more frequent during up titration of Trileptal dose.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>diplopia.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>vision blurred, visual disturbance.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>vertigo.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>atrioventricular block, arrhythmia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>hypertension.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>vomiting, nausea.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea, abdominal pain, constipation.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>pancreatitis and/or lipase and/or amylase increase.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>hepatitis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash, alopecia, acne.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>urticaria.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p>Not known</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&rsquo;s syndrome), angioedema, erythema multiforme (see section 4.4).</p><p>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)**, Acute Generalized Exanthematous Pustulosis (AGEP)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>systemic lupus erythematosus.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with Trileptal. The mechanism by which Trileptal affects bone metabolism has not been identified.</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>fatigue.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>asthenia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hepatic enzymes increased, blood alkaline phosphatase increased.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>decrease in T4 (with unclear clinical significance).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Fall</p></td></tr></tbody></table><p>&nbsp;</p><p><u>b.Description of selected adverse reactions</u></p><p><strong><sup>#</sup></strong>Hypersensitivity (including multi-organ hypersensitivity) characterised by features such as rash, fever. Other organs or systems may be affected such as blood and lymphatic system (e.g. eosinophilia, thrombocytopenia, leucopenia, lymphadenopathy, splenomegaly), liver (e.g. hepatitis, abnormal liver function tests), muscles and joints (e.g. joint swelling, myalgia, arthralgia), nervous system (e.g. hepatic encephalopathy), kidneys (e.g. renal failure, nephritis interstitial, proteinuria), lungs (e.g. pulmonary oedema, asthma, bronchospasms, interstitial lung disease, dyspnea), angioedema.</p><p>&nbsp;</p><p><sup>&dagger; </sup>Serum sodium levels below 125&nbsp;mmol/l have been observed in up to 2.7&nbsp;% of Trileptal treated patients with frequency common (see section 4.4).&nbsp; In most cases, the hyponatriaemia is asymptomatic and does not require adjustment of therapy,</p><p>&nbsp;</p><p>Very rarely, the hyponatraemia is associated with signs and symptoms such as seizures, encephalopathy, depressed level of consciousness, confusion, (see also Nervous system disorders for further undesirable effects), vision disorders (e.g. blurred vision), hypothyroidism, vomiting, and nausea. Low serum sodium levels generally occurred during the first 3 months of treatment with Trileptal, although there were patients who first developed a serum sodium level &lt;125 mmol/l more than 1 year after initiation of therapy (see section 4.4).</p><p>&nbsp;</p><p><em>**Adverse reactions from spontaneous reports and literature cases (frequency not known): </em></p><p>The following adverse reactions have been derived from post-marketing experience with Trileptal via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.</p><p>&nbsp;</p><p><strong>-<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +996112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated cases of overdose have been reported. The maximum dose taken was approximately 48,000 mg.</p><p>&nbsp;</p><p><strong>Symptoms</strong></p><p>Electrolyte and fluid balance conditions: hyponatraemia</p><p>Eye disorders: diplopia, miosis, blurred vision</p><p>Gastrointestinal disorders: nausea, vomiting, hyperkinesia</p><p>General disorders and administration site conditions: fatigue</p><p>Investigations: respiratory rate depression, QTc prolongation</p><p>Nervous system disorders: drowsiness and somnolence, dizziness, ataxia and nystagmus, tremor, disturbances in coordination (coordination abnormal), convulsion, headache, coma, loss of consciousness, dyskinesia</p><p>Psychiatric disorders: aggression, agitation, confusional state</p><p>Vascular disorders: hypotension</p><p>Respiratory, thoracic and mediastinal disorders: dyspnoea</p><p>&nbsp;</p><p><strong>Management</strong></p><p>There is no specific antidote. Symptomatic and supportive treatment should be administered as appropriate. Removal of the medicinal product by gastric lavage and/or inactivation by administering activated charcoal should be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiepileptics, ATC code: N03A F 02</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD) (see section 5.2). The mechanism of action of oxcarbazepine and MHD is thought to be mainly based on the blockade of voltage-sensitive sodium channels, thus resulting in stabilisation of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminishment of propagation of synaptic impulses. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may also contribute to the anticonvulsant effects. No significant interactions with brain neurotransmitter or modulator receptor sites were found.</p><p>&nbsp;</p><p>Oxcarbazepine and its active metabolite (MHD), are potent and efficacious anticonvulsants in animals. They protected rodents against generalised tonic-clonic and, to a lesser degree, clonic seizures, and abolished or reduced the frequency of chronically recurring partial seizures in Rhesus monkeys with aluminum implants. No tolerance (i.e. attenuation of anticonvulsive activity) against tonic-clonic seizures was observed when mice and rats were treated daily for 5 days or 4 weeks, respectively, with oxcarbazepine or MHD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration of Trileptal, oxcarbazepine is completely absorbed and extensively metabolised to its pharmacologically active metabolite (MHD).</p><p>&nbsp;</p><p>After single dose administration of 600&nbsp;mg Trileptal to healthy male volunteers under fasted conditions, the mean C<sub>max</sub> value of MHD was 34&nbsp;mmol/l, with a corresponding median t<sub>max</sub> of 4.5&nbsp;hours.</p><p>&nbsp;</p><p>In a mass balance study in man, only 2&nbsp;% of total radioactivity in plasma was due to unchanged oxcarbazepine, approximately 70&nbsp;% was due to MHD, and the remainder attributable to minor secondary metabolites which were rapidly eliminated.</p><p>&nbsp;</p><p>Food has no effect on the rate and extent of absorption of oxcarbazepine, therefore, Trileptal can be taken with or without food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution of MHD is 49&nbsp;litres.</p><p>&nbsp;</p><p>Approximately 40&nbsp;% of MHD, is bound to serum proteins, predominantly to albumin. Binding was independent of the serum concentration within the therapeutically relevant range. Oxcarbazepine and MHD do not bind to alpha-1-acid glycoprotein.</p><p>&nbsp;</p><p>Oxcarbazepine and MHD cross the placenta. Neonatal and maternal plasma MHD concentrations were similar in one case.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Oxcarbazepine is rapidly reduced by cytosolic enzymes in the liver to MHD, which is primarily responsible for the pharmacological effect of Trileptal. MHD is metabolised further by conjugation with glucuronic acid. Minor amounts (4&nbsp;% of the dose) are oxidised to the pharmacologically inactive metabolite (10,&nbsp;11-dihydroxy derivative, DHD).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Oxcarbazepine is cleared from the body mostly in the form of metabolites which are predominantly excreted by the kidneys. More than 95&nbsp;% of the dose appears in the urine, with less than 1&nbsp;% as unchanged oxcarbazepine. Faecal excretion accounts for less than 4&nbsp;% of the administered dose. Approximately 80&nbsp;% of the dose is excreted in the urine either as glucuronides of MHD (49&nbsp;%) or as unchanged MHD (27&nbsp;%), whereas the inactive DHD accounts for approximately 3&nbsp;% and conjugates of oxcarbazepine account for 13&nbsp;% of the dose.</p><p>&nbsp;</p><p>Oxcarbazepine is rapidly eliminated from the plasma with apparent half-life values between 1.3 and 2.3&nbsp;hours. In contrast, the apparent plasma half-life of MHD averaged 9.3&nbsp;&plusmn;&nbsp;1.8&nbsp;h.</p><p>&nbsp;</p><p><u>Dose proportionality</u></p><p>Steady-state plasma concentrations of MHD are reached within 2&nbsp;-&nbsp;3 days in patients when Trileptal is given twice a day. At steady-state, the pharmacokinetics of MHD are linear and show dose proportionality across the dose range of 300 to 2,400&nbsp;mg/day.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Patients with hepatic impairment</em></p><p>The pharmacokinetics and metabolism of oxcarbazepine and MHD were evaluated in healthy volunteers and hepatically-impaired subjects after a single 900&nbsp;mg oral dose. Mild to moderate hepatic impairment did not affect the pharmacokinetics of oxcarbazepine and MHD. Trileptal has not been studied in patients with severe hepatic impairment.</p><p><em>&nbsp;</em></p><p><em>Patients with renal impairment</em></p><p>There is a linear correlation between creatinine clearance and the renal clearance of MHD. When Trileptal is administered as a single 300&nbsp;mg dose, in renally impaired patients (creatinine clearance &lt;&nbsp;30&nbsp;mL/min) the elimination half-life of MHD is prolonged by 60-90&nbsp;% (16 to 19 hours) with a two fold increase in AUC compared to adults with normal renal function (10 hours).</p><p>&nbsp;</p><p><em>Children</em></p><p>The pharmacokinetics of Trileptal were evaluated in clinical trials in paediatric patients taking Trileptal in the dose range 10-60 mg/kg/day. Weight-adjusted MHD clearance decreases as age and weight increases approaching that of adults. The mean weight-adjusted clearance in children 4 to 12 years of age is approximately 40% higher than that of adults. Therefore, MHD exposure in these children is expected to be about two-thirds that of adults when treated with a similar weight-adjusted dose. As weight increases, for patients 13 years of age and above, the weight-adjusted MHD clearance is expected to reach that of adults.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>Data from a limited number of women indicate that MHD plasma levels may gradually decrease throughout pregnancy (see section 4.6).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Following administration of single (300&nbsp;mg) and multiple doses (600&nbsp;mg/day) of Trileptal in elderly volunteers (60&nbsp;-&nbsp;82&nbsp;years of age), the maximum plasma concentrations and AUC values of MHD were 30&nbsp;%&nbsp;-&nbsp;60&nbsp;% higher than in younger volunteers (18&nbsp;-&nbsp;32&nbsp;years of age). Comparisons of creatinine clearances in young and elderly volunteers indicate that the difference was due to age-related reductions in creatinine clearance. No special dose recommendations are necessary because therapeutic doses are individually adjusted.</p><p>&nbsp;</p><p><em>Gender</em></p><p>No gender related pharmacokinetic differences have been observed in children, adults, or the elderly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data indicated no special hazard for humans based on safety pharmacology and genotoxicity studies with oxcarbazepine and the pharmacologically active metabolite, monohydroxy derivative (MHD).</p><p>&nbsp;</p><p>Evidence of nephrotoxicity was noted in repeated dose toxicity rat studies but not in dog or mice studies.</p><p>&nbsp;</p><p><u>Immunotoxicity </u></p><p>Immunostimulatory tests in mice showed that MHD (and to a lesser extent oxcarbazepine) can induce delayed hypersensitivity.</p><p>&nbsp;</p><p><u>Mutagenicity </u></p><p>Oxcarbazepine increased mutation frequencies in one Ames test in vitro in the absence of metabolic activation in one of five bacterial strains. Oxcarbazepine and MHD produced increases in chromosomal aberrations and/or polyploidy in the Chinese hamster ovary assay in vitro in the absence of metabolic activation. MHD was negative in the Ames test, and no mutagenic or clastogenic activity was found with either oxcarbazepine or MHD in V79 Chinese hamster cells in vitro. Oxcarbazepine and MHD were both negative for clastogenic or aneugenic effects (micronucleus formation) in an in vivo rat bone marrow assay.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>In rats, fertility in both sexes was unaffected by oxcarbazepine at oral doses up to 150 mg/kg/day, at which there is no safety margin. Disruption of estrous cyclicity and reduced numbers of corpora lutea, implantations and live embryos were observed in female animals for MHD at doses comparable to those in humans (see section 4.6).</p><p><u>&nbsp;</u></p><p>Standard reproductive toxicity studies in rodents and rabbits revealed effects such as increases in the incidence of embryo-foetal mortality and/or some delay in antenatal and/or postnatal growth of the offspring at maternally toxic dose levels. There was an increase in rat foetal malformations in one of the eight embryo-foetal toxicity studies, which were conducted with either oxcarbazepine or MHD, at doses which also caused maternal toxicity (see section 4.6).</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>In the carcinogenicity studies, liver (rats and mice), testicular and female genital tract granular cell (rats) tumours were induced in treated animals. The occurrence of liver tumours was most likely a consequence of the induction of hepatic microsomal enzymes; an inductive effect which, although it cannot be excluded, is weak or absent in patients treated with Trileptal. Testicular tumours may have been induced by elevated luteinizing hormone concentrations. Due to the absence of such an increase in humans, these tumours are considered to be of no clinical relevance. A dose-related increase in the incidence of granular cell tumours of the female genital tract (cervix and vagina) was noted in the rat carcinogenicity study with MHD. These effects occurred at exposure levels comparable with the anticipated clinical exposure. The mechanism for the development of these tumours has not been fully elucidated but could be related to increased estradiol levels specific to the rat. The clinical relevance of these tumours is unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Tablet core: </u></p><p>silica, colloidal anhydrous</p><p>cellulose, microcrystalline</p><p>hypromellose</p><p>crospovidone</p><p>magnesium stearate.</p><p>&nbsp;</p><p><u>Tablet coating:</u></p><p>hypromellose</p><p>talc</p><p>titanium dioxide (E 171).</p><p>&nbsp;</p><p><em>150 mg tablet coating only:</em></p><p>macrogol 4000</p><p>iron oxide, yellow (E 172)</p><p>iron oxide red (E 172)</p><p>iron oxide black (E 172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister containing 10 tablets. Blister material: PVC/PE/PVDC with aluminium foil backing.</p><p>&nbsp;</p><p>Blister pack of 30, 50, 100, 200 and/or 500 tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by MHRA on May 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>